All Posts By

Smartkarma Daily Briefs

Most Read: Benefit One Inc, Yamazen Corp, S.M.Entertainment Co, Shinko Electric Industries, Denso Corp, CPMC Holdings, Tongcheng Travel Holdings and more

By | Daily Briefs, Most Read

In today’s briefing:

  • Denso Corp Placement – Quick Update – In Better Shape Now, Size Concern Remains
  • Benefit One (2412): M3 Extends For a Full Month
  • Yamazen Secondary Offer (8150 JP) – 5 Banks Sell To Make This a Future Activism Target
  • A Review of Tender Offers of Korean Companies in 2023
  • JIC Consortium Possibly In Line to Win Shinko At “¥800bn”, Which Makes You Go 🤔…
  • Shinko Electric (6967 JP): JIC’s Pre-Conditional Tender Offer at JPY5,920
  • Denso (6902 JP): The Current Playbook
  • CPMC (906 HK): SASAC Usurper?
  • CPMC Holdings (906 HK): Possible Scenarios as ORG Mulls a Competing Offer
  • HSTECH Index Rebalance Preview: Tongcheng Travel (780 HK) Could Replace GDS (9698 HK)


Denso Corp Placement – Quick Update – In Better Shape Now, Size Concern Remains

By Sumeet Singh

  • On 28th Nov 2023, Toyota Motor (7203 JP) announced that it would sell around 9.4% of Denso Corp (6902 JP) in order to reduce its cross-shareholding.
  • The shares hadn’t corrected much till our last note on 7th Dec 2023, they have since corrected by 6% .
  • We have covered the deal background and deal dynamics in our earlier notes. In this note, we talk about the recent share price movement, as compared to prior deals.

Benefit One (2412): M3 Extends For a Full Month

By Travis Lundy

  • Today after the close, Benefit One Inc (2412 JP) amended its Tender Offer Target Opinion Statement to note that Dai Ichi Life had made a proposal to acquire 100%.
  • To allow the Board time to evaluate this proposal, the Company requested a Tender extension. Bidder M3 Inc (2413 JP) was obliged to extend 10 days. They extended 20 days.
  • This tells us a bunch of things. It is worth thinking about what happened to get here.

Yamazen Secondary Offer (8150 JP) – 5 Banks Sell To Make This a Future Activism Target

By Travis Lundy

  • On Monday after the close, trading house Yamazen Corp (8051 JP) announced a secondary offering where five bank shareholders would sell ~6.7mm shares (including greenshoe). 
  • It appears as if most of the banks are selling everything, making it about US$50mm, 50 days of ADV, and about 7% of  shares out. 
  • But this should get swallowed pretty easily. The stock is DIRT CHEAP. The caveat? Crossholders and insiders will still own 45-48% post-offer. 

A Review of Tender Offers of Korean Companies in 2023

By Douglas Kim

  • We review the major tender offers of Korean companies in 2023. Some of the major M&A tender offers that have closed this year include Osstem Implant and SM Entertainment.
  • Among the 15 companies targeted for tender offers, there are 5 companies including Osstem Implant, SM Entertainment, Lutronic Corp where the purpose of the tender offers is for M&A. 
  • There were a total of 18 companies that submitted tender offer results announcements in 2023 (as of 11 December), up 157% YoY.

JIC Consortium Possibly In Line to Win Shinko At “¥800bn”, Which Makes You Go 🤔…

By Travis Lundy

  • A Nikkei article today suggested that Fujitsu had granted preferential negotiating rights to buy Shinko Electric Industries (6967 JP) to a JIC-led consortium (including DNP and Mitsui Chem) for ~¥800bn.
  • This happened late in the afternoon session. Shares spiked 5+%, then were halted. A gray market ensued. 
  • A Bloomberg article provided more info, and the same info nuanced slightly differently. The wording in yet other articles was interesting enough that it is worth discussing. 

Shinko Electric (6967 JP): JIC’s Pre-Conditional Tender Offer at JPY5,920

By Arun George

  • After months of speculation, Shinko Electric Industries (6967 JP) has recommended the JIC alliance’s preconditional tender offer of JPY5,920 per share, an 18.9% premium to the undisturbed price (31 May). 
  • The pre-condition relates to regulatory approvals in Japan, China, Korea, and possibly Vietnam. The offeror may waive the pre-condition. The offer is long-dated and expected to start in August 2024.
  • The minimum acceptance condition requires a 33.3% minority acceptance rate. Despite the low 7.1% premium to the last close, the offer resulted from a competing bidding process. 

Denso (6902 JP): The Current Playbook

By Arun George

  • Since the US$4.0 billion secondary placement announcement, Denso Corp (6902 JP)’s shares are down 4.3% from the undisturbed price of JPY2,298 per share (28 November).
  • Looking at recent large Japanese placements is instructive to understand the potential trading pattern. So far, Denso’s shares have followed the pattern of previous large placements.
  • The offering will likely be priced on 13 December. Investors participating in previous large Japanese placements tend to secure positive returns.

CPMC (906 HK): SASAC Usurper?

By David Blennerhassett

  • In what I viewed as one of the cleaner deals, CPMC Holdings (906 HK) announced a pre-conditional Offer from SASAC and the National Council for Social Security Fund of China.
  • A decent premium to undisturbed, a low tendering threshold, and a large shareholder giving an irrevocable – this looked done. 
  • Now ORG Development Limited/ORG Technology Co., Ltd. A (002701 CH), holding 24.4% of shares out, is mulling a competing conditional general cash Offer. One of these Offers will get up.

CPMC Holdings (906 HK): Possible Scenarios as ORG Mulls a Competing Offer

By Arun George

  • CPMC Holdings (906 HK) disclosed that ORG Technology Co., Ltd. A (002701 CH), the second-largest shareholder, is considering a competing voluntary conditional general cash offer.
  • It is rare to bid against an SOE bidder. ORG likely has implicit SOE support to launch a competing offer due to the need for Chinese regulatory approvals. 
  • The possible scenarios suggest Mr Zhang Wei is the winning bid’s kingmaker. Mr Wei sold down 260K shares at HK$6.35 on 8 December, indicating a willingness to exit.

HSTECH Index Rebalance Preview: Tongcheng Travel (780 HK) Could Replace GDS (9698 HK)

By Brian Freitas


💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Analytics and News
  • ✓ Events & Webinars



Daily Brief United States: Hollysys Automation Technologies, Immix Biopharma Inc and more

By | Daily Briefs, United States

In today’s briefing:

  • Hollysys Gives Ascendent Capital The Nod. Agnostic Shareholders Will Approve
  • Immix Biopharma – Encouraging stream of ALA data newsflow


Hollysys Gives Ascendent Capital The Nod. Agnostic Shareholders Will Approve

By David Blennerhassett

  • Hollysys Automation Technologies (HOLI US)‘s board persistent stonewalling was effectively terminated after the its court injunction was dismissed last month. An SGM will now take place sometime next month.  
  • A firm merger agreement was expected this month, and Hollysys announced yesterday Ascendent Capital has emerged as the preferred suitor with a (revised) US$26.50/share Offer. 
  • This looks to be (finally) all stitched up. Trading wide-ish to terms. Get involved. 

Immix Biopharma – Encouraging stream of ALA data newsflow

By Edison Investment Research

Immix presented encouraging new data at the American Society of Hematology (ASH) 2023 meeting for its Nexcella subsidiary’s lead CAR-T asset, NXC-201, in amyloid light chain amyloidosis (ALA) patients. The update corresponds to 10 ALA patients treated with NXC-201, for which the overall response rate (ORR) stands at 100% (10/10). NXC-201 also maintains its competitive safety profile among this group, including no cases of neurotoxicity and only low-grade cytokine release syndrome associated with short onset and duration. The results to date are supportive of NXC-201 potentially becoming the first outpatient CAR-T therapy, in our view, offering a potentially desirable treatment option for a fragile patient population. While the current data come from the NEXICART-1 trial based in Israel, with the Investigational New Drug (IND) application in ALA patients recently accepted by the FDA, we believe the enrolment of patients at US trial sites (NEXICART-2) will be a key milestone for the clinical progression of NXC-201. Management has communicated that it intends to submit a Biologics License Application to the FDA once 30–40 ALA patients have been treated.


💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Daily Brief India: RPSG Ventures Limited, Alkem Laboratories Ltd and more

By | Daily Briefs, India

In today’s briefing:

  • RPSG Ventures: Q2FY24 Earnings Update
  • Alkem Laboratories Ltd (ALKEM IN): Further Upside on Card on US Business and Margin Improvement


RPSG Ventures: Q2FY24 Earnings Update

By Ankit Agrawal, CFA

  • RPSGV’s BPO business, Firstsource Solutions, is stabilizing and reported flattish QoQ revenue growth. EBIT margin has also bottomed out and is now at around 11%, an expansion of 300bp YoY.
  • FMCG Business continues to maintain an annualized revenue run-rate of INR 400cr+. The Sports business generated revenues of INR 50cr+ vs INR 15cr YoY. 
  • The FMCG and the Sports businesses hold tremendous scalability potential going forward. The IPL Lucknow franchise also owns a team named Durban in the South Africa T20 league.

Alkem Laboratories Ltd (ALKEM IN): Further Upside on Card on US Business and Margin Improvement

By Tina Banerjee

  • Alkem Laboratories Ltd (ALKEM IN) is flying high on strong Q2 numbers. The shares rallied 23% since the company announced Q2FY24 result in early November, widely outperforming Nifty Pharma index.
  • In Q2FY24, revenue grew 12% YoY, and gross margin expanded 380bps to 61.4% backed by lower raw material cost and lower intensity of price erosion in US market.
  • For the U.S. business, Alkem is looking at high-single-digit growth in dollar terms for FY24. The company has reiterated FY24 gross margin guidance at 59.0–59.5%.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Daily Brief ESG: Unification of Quarterly Reports Will Further Increase the Role of TSE and more

By | Daily Briefs, ESG

In today’s briefing:

  • Unification of Quarterly Reports Will Further Increase the Role of TSE


Unification of Quarterly Reports Will Further Increase the Role of TSE

By Aki Matsumoto

  • The contents of quarterly reports are the same as those of financial summaries. Therefore, it’s in order that the quarterly reports for 1Q /3Q be unified with the financial summaries.
  • The major difference between quarterly securities reports and financial summaries is the significance of legal responsibility. By requiring partial review by auditors, TSE will ensure the reliability of financial summaries.
  • Meanwhile, TSE must continue to enhance the ethics of company managers and require companies to eliminate malicious misreporting. Unification of quarterly reports would further increase the role of the TSE.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Daily Brief China: CPMC Holdings, Tongcheng Travel Holdings , Tencent, REPT BATTERO Energy, China Shineway Pharmaceutical, Meitu Inc and more

By | China, Daily Briefs

In today’s briefing:

  • CPMC (906 HK): SASAC Usurper?
  • CPMC Holdings (906 HK): Possible Scenarios as ORG Mulls a Competing Offer
  • HSTECH Index Rebalance Preview: Tongcheng Travel (780 HK) Could Replace GDS (9698 HK)
  • Tencent/Netease: Game Approval Skewed Towards Netease in ’23
  • CPMC Holdings (906 HK): Another Potential Contender
  • REPT BATTERO IPO Preview and Valuation Analysis: Burning Cash and Rising Debt Ahead of the IPO
  • China Shineway Pharmaceutical (2877.HK) – Performance Pressure Is About to Emerge
  • HK CEO & Director Dealings (13 Dec 2023): Meitu’s NED Selling; China HK Power’s Short Call


CPMC (906 HK): SASAC Usurper?

By David Blennerhassett

  • In what I viewed as one of the cleaner deals, CPMC Holdings (906 HK) announced a pre-conditional Offer from SASAC and the National Council for Social Security Fund of China.
  • A decent premium to undisturbed, a low tendering threshold, and a large shareholder giving an irrevocable – this looked done. 
  • Now ORG Development Limited/ORG Technology Co., Ltd. A (002701 CH), holding 24.4% of shares out, is mulling a competing conditional general cash Offer. One of these Offers will get up.

CPMC Holdings (906 HK): Possible Scenarios as ORG Mulls a Competing Offer

By Arun George

  • CPMC Holdings (906 HK) disclosed that ORG Technology Co., Ltd. A (002701 CH), the second-largest shareholder, is considering a competing voluntary conditional general cash offer.
  • It is rare to bid against an SOE bidder. ORG likely has implicit SOE support to launch a competing offer due to the need for Chinese regulatory approvals. 
  • The possible scenarios suggest Mr Zhang Wei is the winning bid’s kingmaker. Mr Wei sold down 260K shares at HK$6.35 on 8 December, indicating a willingness to exit.

HSTECH Index Rebalance Preview: Tongcheng Travel (780 HK) Could Replace GDS (9698 HK)

By Brian Freitas


Tencent/Netease: Game Approval Skewed Towards Netease in ’23

By Ke Yan, CFA, FRM

  • China announced game approval for November batch. The number of games approved is in-line with the pace of approval in recent months.
  • The Pace of China game approval stays flattish, at a much slower pace than pre-tightening.
  • Netease scored one approval while Tencent has been zeroed for five rounds.

CPMC Holdings (906 HK): Another Potential Contender

By Osbert Tang, CFA

  • CPMC Holdings (906 HK) may potentially receive another takeover proposal from ORG Technology Co., Ltd. A (002701 CH) which has a 22% market share in the industry.
  • ORG has every reason to launch such a proposal and given its operational and financial performance, it looks to have the capability to realise good synergy.
  • CPMC still looks inexpensive relative to the industry based on its PER valuations. No matter what, the 4th largest player Sunrise Group (002752 CH) will now become interesting.

REPT BATTERO IPO Preview and Valuation Analysis: Burning Cash and Rising Debt Ahead of the IPO

By Andrei Zakharov

  • REPT BATTERO, a Chinese Li-ion battery manufacturer, announced terms for its IPO in Hong Kong. The initial public offering price is expected to be between HK$18.20 and HK$20.60 per share.  
  • The company plans to raise ~HK$2.1B of net proceeds at HK$19.40/share. REPT BATTERO will begin trading on the Hong Kong Stock Exchange under the stock code 0666 on December 18.
  • I have a negative view of the upcoming REPT BATTERO IPO and expect the stock will underperform during the first trading day as a publicly listed company. 

China Shineway Pharmaceutical (2877.HK) – Performance Pressure Is About to Emerge

By Xinyao (Criss) Wang

  • Shineway’s performance growth in 23Q1-Q3 slowed obviously. The big decrease in sales growth of injection products and TCM formula granule products would drag down the overall revenue growth in 23H2. 
  • Due to TCM formula granules VBP, the 60%-75% gross profit margin level is hard to sustain. TCM formula granules business would enter an era of low profits but high sales.
  • Shineway’s cash balance is RMB5.4 billion, but market value is about RMB5.39 billion. So, Shineway is undervalued. The Company’s two dividends next year could reach RMB50 cents per share.

HK CEO & Director Dealings (13 Dec 2023): Meitu’s NED Selling; China HK Power’s Short Call

By David Blennerhassett

  • The data in this insight is collated from the “shareholding disclosure” link on the HKEx website.
  • Often there is a corresponding HKEx announcement on the increase – or decrease – in the shareholding by directors. Or pledging. However, such disclosures are by no means an absolute.
  • The key stocks mentioned in this regular insight are China HK Power (931 HK)and Meitu Inc (1357 HK)

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Daily Brief Japan: Benefit One Inc, Shinko Electric Industries, Denso Corp, Money Forward , TSE Tokyo Price Index TOPIX, Will Group Inc and more

By | Daily Briefs, Japan

In today’s briefing:

  • Benefit One (2412): M3 Extends For a Full Month
  • JIC Consortium Possibly In Line to Win Shinko At “¥800bn”, Which Makes You Go 🤔…
  • Shinko Electric (6967 JP): JIC’s Pre-Conditional Tender Offer at JPY5,920
  • Denso (6902 JP): The Current Playbook
  • Money Forward (3394) | A Growth Stock for 2024
  • Unification of Quarterly Reports Will Further Increase the Role of TSE
  • 2Q Follow-Up – Will Group (6089 JP)


Benefit One (2412): M3 Extends For a Full Month

By Travis Lundy

  • Today after the close, Benefit One Inc (2412 JP) amended its Tender Offer Target Opinion Statement to note that Dai Ichi Life had made a proposal to acquire 100%.
  • To allow the Board time to evaluate this proposal, the Company requested a Tender extension. Bidder M3 Inc (2413 JP) was obliged to extend 10 days. They extended 20 days.
  • This tells us a bunch of things. It is worth thinking about what happened to get here.

JIC Consortium Possibly In Line to Win Shinko At “¥800bn”, Which Makes You Go 🤔…

By Travis Lundy

  • A Nikkei article today suggested that Fujitsu had granted preferential negotiating rights to buy Shinko Electric Industries (6967 JP) to a JIC-led consortium (including DNP and Mitsui Chem) for ~¥800bn.
  • This happened late in the afternoon session. Shares spiked 5+%, then were halted. A gray market ensued. 
  • A Bloomberg article provided more info, and the same info nuanced slightly differently. The wording in yet other articles was interesting enough that it is worth discussing. 

Shinko Electric (6967 JP): JIC’s Pre-Conditional Tender Offer at JPY5,920

By Arun George

  • After months of speculation, Shinko Electric Industries (6967 JP) has recommended the JIC alliance’s preconditional tender offer of JPY5,920 per share, an 18.9% premium to the undisturbed price (31 May). 
  • The pre-condition relates to regulatory approvals in Japan, China, Korea, and possibly Vietnam. The offeror may waive the pre-condition. The offer is long-dated and expected to start in August 2024.
  • The minimum acceptance condition requires a 33.3% minority acceptance rate. Despite the low 7.1% premium to the last close, the offer resulted from a competing bidding process. 

Denso (6902 JP): The Current Playbook

By Arun George

  • Since the US$4.0 billion secondary placement announcement, Denso Corp (6902 JP)’s shares are down 4.3% from the undisturbed price of JPY2,298 per share (28 November).
  • Looking at recent large Japanese placements is instructive to understand the potential trading pattern. So far, Denso’s shares have followed the pattern of previous large placements.
  • The offering will likely be priced on 13 December. Investors participating in previous large Japanese placements tend to secure positive returns.

Money Forward (3394) | A Growth Stock for 2024

By Mark Chadwick

  • Money Forward’s stock price has declined by 2% YTD versus a 23% gain for the overall market. Technically, the stock is approaching oversold levels
  • We see 38% upside for Money Forward’s stock price. At 5.5x EV/revenue, the stock is trading at a 50% discount to global peer, Intuit
  • We believe that investors are under pricing the size of the Japanese market for cloud accounting and operating leverage from penetration into mid-cap corporate market

Unification of Quarterly Reports Will Further Increase the Role of TSE

By Aki Matsumoto

  • The contents of quarterly reports are the same as those of financial summaries. Therefore, it’s in order that the quarterly reports for 1Q /3Q be unified with the financial summaries.
  • The major difference between quarterly securities reports and financial summaries is the significance of legal responsibility. By requiring partial review by auditors, TSE will ensure the reliability of financial summaries.
  • Meanwhile, TSE must continue to enhance the ethics of company managers and require companies to eliminate malicious misreporting. Unification of quarterly reports would further increase the role of the TSE.

2Q Follow-Up – Will Group (6089 JP)

By Sessa Investment Research

  • WILL GROUP unveiled its new MTP “WILL-being 2026” this May.
  • The aim of the previous MTP “WORK SHIFT Strategy” was to boost profit margins by increasing the weight of high-margin permanent placement and temporary staffing in highly specialized fields, and the Company focused on developing strategic investment domains such as nursing care domain support, support for construction management engineers, and HR support for start-up companies.
  • In the previous MTP, although the profit margin improved, Domestic Working Business stagnated. 

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Daily Brief Thematic (Sector/Industry): Ohayo Japan | CPI Sends Stocks to New Highs and more

By | Daily Briefs, Thematic (Sector/Industry)

In today’s briefing:

  • Ohayo Japan | CPI Sends Stocks to New Highs
  • [Blue Lotus Daily – TMT Update]:700 HK/BABA/Temu/Shein/PDD/CPNG/SE/AMZN/MELI/JD/1024 HK/2618 HK
  • [Blue Lotus Daily]: BABA/TCOM/NIO/HTHT/ATAT
  • Indian Contract Manufacturers: A Pair Trade Idea Between Gland Pharma and Syngene International


Ohayo Japan | CPI Sends Stocks to New Highs

By Mark Chadwick

  • Overseas: SPX +0.5%; US Consumer prices +3.1% YoY; Oracle shares down -12% after Q2 miss
  • Today: NKY Futs flat v cash. JPY 145.5; Renault initiates the sale of a 5% stake in Nissan
  • Murakami takes 5.9% stake in Glosel; Macnica’s bid was too cheap. Expect a bump

[Blue Lotus Daily – TMT Update]:700 HK/BABA/Temu/Shein/PDD/CPNG/SE/AMZN/MELI/JD/1024 HK/2618 HK

By Ying Pan

  • BABA/MELI/PDD/Shein/1519 HK: Cainiao launches charter flight route to Mexico (+/+/-/-/-/)
  • 700 HK: Tencent gaming studio <Level Infinite> announced 4 new games at The Game Award 2023(+)
  • BABA/Temu/Shein/CPNG/SE/AMZN/MELI: Alibaba plans to launch LLM AI-powered <1688> in South Korea(+/+/+/+/+/-/-)

[Blue Lotus Daily]: BABA/TCOM/NIO/HTHT/ATAT

By Eric Wen

  • BABA/TCOM: China Tourism – Singapore and China to establish mutual 30-day visa exemption (+)
  • NIO: NIO Auto to spin off its battery manufacturing business for financing (+)
  • HTHT/ATAT: China Tourism Update – Chinese Embassies abroad temporarily reduce visa fees (+)

Indian Contract Manufacturers: A Pair Trade Idea Between Gland Pharma and Syngene International

By Tina Banerjee

  • We are recommending to go long on Gland Pharma Ltd (GLAND IN) and short on Syngene International Ltd (SYNG IN)
  • Gland Pharma, with its niche focus on generic injectables is expected to be outlier, while Syngene, with substantial exposure to early-stage biotech research will continue to have muted performance.
  • Over the last six months, Gland Pharma shares rallied 83%, while Syngene International shares declined 5%. We expect the performance gap between the two companies will widen further.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Daily Brief ECM: Denso (6902 JP): The Current Playbook and more

By | Daily Briefs, ECM

In today’s briefing:

  • Denso (6902 JP): The Current Playbook
  • REPT BATTERO IPO Preview and Valuation Analysis: Burning Cash and Rising Debt Ahead of the IPO


Denso (6902 JP): The Current Playbook

By Arun George

  • Since the US$4.0 billion secondary placement announcement, Denso Corp (6902 JP)’s shares are down 4.3% from the undisturbed price of JPY2,298 per share (28 November).
  • Looking at recent large Japanese placements is instructive to understand the potential trading pattern. So far, Denso’s shares have followed the pattern of previous large placements.
  • The offering will likely be priced on 13 December. Investors participating in previous large Japanese placements tend to secure positive returns.

REPT BATTERO IPO Preview and Valuation Analysis: Burning Cash and Rising Debt Ahead of the IPO

By Andrei Zakharov

  • REPT BATTERO, a Chinese Li-ion battery manufacturer, announced terms for its IPO in Hong Kong. The initial public offering price is expected to be between HK$18.20 and HK$20.60 per share.  
  • The company plans to raise ~HK$2.1B of net proceeds at HK$19.40/share. REPT BATTERO will begin trading on the Hong Kong Stock Exchange under the stock code 0666 on December 18.
  • I have a negative view of the upcoming REPT BATTERO IPO and expect the stock will underperform during the first trading day as a publicly listed company. 

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Daily Brief Credit: Morning Views Asia: Wynn Macau Ltd and more

By | Credit, Daily Briefs

In today’s briefing:

  • Morning Views Asia: Wynn Macau Ltd


Morning Views Asia: Wynn Macau Ltd

By Charles Macgregor

Lucror Analytics Morning Views comprise our fundamental credit analysis, opinions and trade recommendations on high yield issuers in the region, based on key company-specific developments in the past 24 hours. Our Morning Views include a section with a brief market commentary, key market indicators and a macroeconomic and corporate event calendar.


💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Daily Brief Equity Bottom-Up: Money Forward (3394) | A Growth Stock for 2024 and more

By | Daily Briefs, Equity Bottom-Up

In today’s briefing:

  • Money Forward (3394) | A Growth Stock for 2024
  • TSMC’s November Revenue Declines 15.3% MoM.
  • Tencent/Netease: Game Approval Skewed Towards Netease in ’23
  • MediaTek (2454.TT): The WiFi 7 Chip Competition Is Likely to Become Fierce in 2024.
  • CPMC Holdings (906 HK): Another Potential Contender
  • OUE Commercial REIT (OUECT SP) – Well-Heeled Exposure to Singapore’s Commercial Property
  • 2024 High Conviction: [KT&G – Likely To Announce Cigarette Price Hikes in 2H24]
  • RPSG Ventures: Q2FY24 Earnings Update
  • Baillie Gifford China Growth Trust – China’s recovery well worth the wait
  • Alkem Laboratories Ltd (ALKEM IN): Further Upside on Card on US Business and Margin Improvement


Money Forward (3394) | A Growth Stock for 2024

By Mark Chadwick

  • Money Forward’s stock price has declined by 2% YTD versus a 23% gain for the overall market. Technically, the stock is approaching oversold levels
  • We see 38% upside for Money Forward’s stock price. At 5.5x EV/revenue, the stock is trading at a 50% discount to global peer, Intuit
  • We believe that investors are under pricing the size of the Japanese market for cloud accounting and operating leverage from penetration into mid-cap corporate market

TSMC’s November Revenue Declines 15.3% MoM.

By William Keating

  • Revenue for November 2023 was NT$206.03 billion, a decrease of 15.3% MoM, and down 7.5% compared to the year ago period.
  • Based on the guided midpoint, December revenue will show a further 20% MoM decline
  • We estimate FY2023 revenues of $68.8 billion, down 9.4% YoY. 

Tencent/Netease: Game Approval Skewed Towards Netease in ’23

By Ke Yan, CFA, FRM

  • China announced game approval for November batch. The number of games approved is in-line with the pace of approval in recent months.
  • The Pace of China game approval stays flattish, at a much slower pace than pre-tightening.
  • Netease scored one approval while Tencent has been zeroed for five rounds.

MediaTek (2454.TT): The WiFi 7 Chip Competition Is Likely to Become Fierce in 2024.

By Patrick Liao

  • The WiFi technology was dominated by Broadcom Corp Cl A (BRCM US), but Mediatek Inc (2454 TT) has to break into the PC and smartphone markets in 2024F.
  • There are speculations that Apple might use MediaTek’s WiFi 7 solution in 2024F or consider MediaTek as a potential chip provider.
  • MediaTek will be using 6nm technology for WiFi 7, replacing the current 28nm technology used for WiFi 6.

CPMC Holdings (906 HK): Another Potential Contender

By Osbert Tang, CFA

  • CPMC Holdings (906 HK) may potentially receive another takeover proposal from ORG Technology Co., Ltd. A (002701 CH) which has a 22% market share in the industry.
  • ORG has every reason to launch such a proposal and given its operational and financial performance, it looks to have the capability to realise good synergy.
  • CPMC still looks inexpensive relative to the industry based on its PER valuations. No matter what, the 4th largest player Sunrise Group (002752 CH) will now become interesting.

OUE Commercial REIT (OUECT SP) – Well-Heeled Exposure to Singapore’s Commercial Property

By Angus Mackintosh

  • OUE Commercial REIT (OUECT SP) is one of Singapore’s best-quality commercial REITs, with a well-diversified and high-quality portfolio of assets across office, hospitality, and retail.
  • A recent Smartkarma webinar with the management revealed a positive outlook for the company’s portfolio across the office, retail, and especially hospitality with some well-times asset enhancement initiatives bearing fruit.
  • OUE Commercial REIT has strong sustainability credentials, both through its green-certified buildings, and an increasing portion of sustainable finance, with some well-timed recent financing. 

2024 High Conviction: [KT&G – Likely To Announce Cigarette Price Hikes in 2H24]

By Douglas Kim

  • KT&G is a high conviction pick in 2024.We believe KT&G Corporation (033780 KS) is likely to announce cigarette price hikes in 2H 2024.
  • Three major reasons include a) no cigarette price hikes in nearly 9 years, b) Korean legislative election will be in April 2024, and c) reduce government tax revenue shortfall.
  • We believe that the Korean government could raise cigarette prices to about 7,000 won to 8,000 won per pack from current price of 4,500 won. 

RPSG Ventures: Q2FY24 Earnings Update

By Ankit Agrawal, CFA

  • RPSGV’s BPO business, Firstsource Solutions, is stabilizing and reported flattish QoQ revenue growth. EBIT margin has also bottomed out and is now at around 11%, an expansion of 300bp YoY.
  • FMCG Business continues to maintain an annualized revenue run-rate of INR 400cr+. The Sports business generated revenues of INR 50cr+ vs INR 15cr YoY. 
  • The FMCG and the Sports businesses hold tremendous scalability potential going forward. The IPL Lucknow franchise also owns a team named Durban in the South Africa T20 league.

Baillie Gifford China Growth Trust – China’s recovery well worth the wait

By Edison Investment Research

Baillie Gifford China Growth Trust (BGCG) invests in China, focusing on innovative, rapidly growing companies best positioned to benefit from China’s still favourable long-term economic outlook and the structural trends that should drive equity markets for years to come. Key portfolio themes include e-commerce, food delivery, domestic brands, semiconductors, robotics and automation, and renewable energy. The trust’s relaunch in September 2020 coincided with a series of challenges for the Chinese economy, investor confidence and the growth companies BGCG favours, so performance has lagged the benchmark. However, the operational performance of most of BGCG’s holdings is strong, their prospects are very positive, and the trust’s managers believe that it is only a matter of time until confidence returns and share prices more accurately reflect these robust fundamentals.


Alkem Laboratories Ltd (ALKEM IN): Further Upside on Card on US Business and Margin Improvement

By Tina Banerjee

  • Alkem Laboratories Ltd (ALKEM IN) is flying high on strong Q2 numbers. The shares rallied 23% since the company announced Q2FY24 result in early November, widely outperforming Nifty Pharma index.
  • In Q2FY24, revenue grew 12% YoY, and gross margin expanded 380bps to 61.4% backed by lower raw material cost and lower intensity of price erosion in US market.
  • For the U.S. business, Alkem is looking at high-single-digit growth in dollar terms for FY24. The company has reiterated FY24 gross margin guidance at 59.0–59.5%.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars